Stock Events

Stock Events

Dyadic International DE 

$0.3500
8
+$0.01+3% 12:14 Today

Statistics

Day High
0.3395
Day Low
0.3395
52W High
1.6
52W Low
0.33
Volume
207
Avg. Volume
-
Mkt Cap
13.61M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 12Expected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.07
-0.06
-0.05
-0.04
Expected EPS
-0.045
Actual EPS
N/A

Financials

-238.35%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
3.09MRevenue
-7.37MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DYAI. It's not an investment recommendation.
Prospect Capital
3
PSEC
Charles Schwab
3
SCHW
Sunrun
3
RUN
Apple
2
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap249.05B
Amgen is a biotechnology company that competes with Dyadic in the development of biopharmaceuticals, leveraging advanced bioprocessing technologies.
Regeneron Pharmaceuticals
REGN
Mkt Cap93.55B
Regeneron Pharmaceuticals is involved in biopharmaceuticals, directly competing with Dyadic in the field of drug development and biologic manufacturing.
Biogen
BIIB
Mkt Cap36.71B
Biogen competes with Dyadic in the biotechnology sector, focusing on the development of therapies for neurological diseases, utilizing advanced biologic production methods.
Vertex Pharmaceuticals
VRTX
Mkt Cap138.71B
Vertex Pharmaceuticals is a competitor in the biotech industry, focusing on creating medicines for serious diseases, similar to Dyadic's focus on biopharmaceuticals.
Gilead Sciences
GILD
Mkt Cap207B
Gilead Sciences is a research-based biopharmaceutical company that competes with Dyadic in developing and commercializing innovative therapeutics.
Adaptive Biotechnologies
ADPT
Mkt Cap4.53B
Adaptive Biotechnologies competes with Dyadic by focusing on the body's immune system to develop products for disease diagnosis and treatment.
CRISPR Therapeutics
CRSP
Mkt Cap4.86B
CRISPR Therapeutics is involved in gene editing, a cutting-edge area of biotechnology that competes with Dyadic's biopharmaceutical development efforts.
Editas Medicine
EDIT
Mkt Cap394.7M
Editas Medicine operates in the genome editing field, directly competing with Dyadic's efforts in leveraging biotechnology for therapeutic development.
Intellia Therapeutics
NTLA
Mkt Cap1.59B
Intellia Therapeutics is a competitor in the CRISPR/Cas9 technology space, relevant to Dyadic's work in biopharmaceuticals and gene therapies.
Alnylam Pharmaceuticals
ALNY
Mkt Cap20.89B
Alnylam Pharmaceuticals competes with Dyadic in the development of RNAi therapeutics, a novel approach to treating disease.

About

Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
Show More
CEO
Mark A. Emalfarb
Employees
5
Country
United States
ISIN
US26745T1016

Listings

XNAS
US
DYAI
BOATS
BOATS
DYAI.BOATS

0 Comments

Share your thoughts

FAQs

What is Dyadic International DE stock price today?▼
The current price of DYAI is $0.35 USD — it has increased by +3% in the past 24 hours. Watch Dyadic International DE stock price performance more closely on the chart.
What is Dyadic International DE stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Dyadic International DE stocks are traded under the ticker DYAI.
Is Dyadic International DE stock price growing?▼
DYAI stock has fallen by -9.63% compared to the previous week, the month change is a -23.49% fall, over the last year Dyadic International DE has showed a -63.65% decrease.
What is Dyadic International DE market cap?▼
Today Dyadic International DE has the market capitalization of 13.61M
When is the next Dyadic International DE earnings date?▼
Dyadic International DE is going to release the next earnings report on November 12, 2026.
What were Dyadic International DE earnings last quarter?▼
DYAI earnings for the last quarter are -0.06 USD per share, whereas the estimation was -0.04 USD resulting in a -71.43% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Dyadic International DE revenue for the last year?▼
Dyadic International DE revenue for the last year amounts to 3.09M USD.
What is Dyadic International DE net income for the last year?▼
DYAI net income for the last year is -7.37M USD.
How many employees does Dyadic International DE have?▼
As of November 9, 2026, the company has 5 employees.
In which sector is Dyadic International DE located?▼
Dyadic International DE operates in the Health & Wellness sector.
When did Dyadic International DE complete a stock split?▼
Dyadic International DE has not had any recent stock splits.
Where is Dyadic International DE headquartered?▼
Dyadic International DE is headquartered in JUPITER, United States.